North America Rare Neurological Disease Treatment Market Forecast to 2027 - Covid-19 Impact and Regional Analysis Indication (Narcolepsy, Amyotrophic Lateral Sclerosis, Alzheimer’s Disease, Multiple Sclerosis, Spinal Muscular Atrophy (SMA), Duchenne Muscular Dystrophy, Other Indication); Drug Type (Organic Compounds, Biologics); Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies); Mode of Administration (Oral, Injectables) and Country
The North America rare neurological disease treatment market is expected to reach US$ 6,113.29 Mn in 2027 from US$ 3,184.10 Mn in 2019. The market is estimated to grow with a CAGR of 8.7% from 2019-2027.
The growth of the market is driven by factors such as the rising prevalence of rare neurological diseases, increasing awareness about rare diseases, and robust pipeline drugs in the North America region. However, higher cost of rare neurological disease treatments is likely to restrain the market growth to a certain extent.
A large group of rare diseases that have inefficient diagnoses and treatments are the neurological disease. These diseases target the nervous system, which include the brain, spinal cord, and all the nerves that run throughout the human body. There is no surety regarding the onset of the diseases; some can strike during childhood, whereas others can affect even highly aged people.
In the world of medicine, rare neurological diseases represent significant burden on health systems in terms of disease diagnosis, treatment, and management. Some of the majorly observed rare neurological diseases comprises narcolepsy, amyotrophic lateral sclerosis, Alzheimer’s disease, multiple sclerosis, spinal muscular atrophy (SMA), Duchenne muscular dystrophy, and others. According to a data published by National Institutes of Neurological Disorders and Stroke in 2019, 7,000 rare neurological diseases have been registered in the US. Additionally, according to the same study, these conditions are responsible for significant number of morbidity and mortality. Additionally, increasing prevalence of rare neurological diseases is expected to drive the growth of the rare neurological disease treatment market during the forecast period.
Rapid developments in healthcare and drug discovery are leading to the introduction of new therapeutic solutions for the treatment of rare neurological diseases. Authorities such as World Health Organization, National Institute of Neurological Disorders and Stroke, and National Institutes of Health are taking constructive steps to encourage the research activities to find a remedy for rare neurological disease treatment. For instance, Neurological disorders, which include more than 1,000 conditions that disrupt the brain and nervous system, affect an estimated 100 million Americans, nearly one third of the US population. With the annual cost of neurological disorders already approaching $800 billion, new treatments that both modify and prevent neurological disease are more critical than ever. Such increasing awareness and developments for rare neurological diseases are likely to boost the growth of the rare neurological disease treatment market in North America during the forecast period.
The increasing use of rare neurological disease treatment in medical treatment cases in North America is expected to drive rare neurological disease treatment market the growing pharmaceuticals industry in the country create a lucrative opportunity and the presence of an established market for rare neurological disease treatment.
Mexico Rare neurological disease treatment Market Revenue and Forecasts to 2027 (US$ Bn)
Get more information on this report :
NORTH AMERICA RARE NEUROLOGICAL DISEASE TREATMENT – MARKET SEGMENTATION
North America Rare Neurological Disease Treatment Market - By Indication
- Narcolepsy
- Amyotrophic Lateral Sclerosis
- Alzheimer’s Disease
- Multiple Sclerosis
- Spinal Muscular Atrophy (SMA)
- Duchenne Muscular Dystrophy
- Other Indications
North America Rare Neurological Disease Treatment Market - By Drug Type
- Organic Compounds
- Biologics
North America Rare Neurological Disease Treatment Market - By Distribution Channel
- Online Pharmacies
- Hospital Pharmacies
- Retail Pharmacies
North America Rare Neurological Disease Treatment Market - By Mode of Administration
North America Rare Neurological Disease Treatment Market - By Country
- US
- Canada
- Mexico
North America Rare Neurological Disease Treatment Market - Companies Mentioned
- Allergan plc.
- Bayer AG
- GlaxoSmithKline plc.
- Johnson & Johnson Services Inc.
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi
- Teva Pharmaceutical Industries Ltd
- Takeda Pharmaceutical Company Limited
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Rare Neurological Disease Treatment Market – By Indication
1.3.2 North America Rare Neurological Disease Treatment Market – By Drug Type
1.3.3 North America Rare Neurological Disease Treatment Market – By Distribution Channel
1.3.4 North America Rare Neurological Disease Treatment Market – By Mode of Administration
1.3.5 North America Rare Neurological Disease Treatment Market – By Country
2. North America Rare Neurological Disease Treatment Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Rare Neurological Disease Treatment Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Rare Neurological Disease Treatment Market - North America PEST Analysis
4.3 Expert Opinion
5. North America Rare Neurological Disease Treatment Market - Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Rising Prevalence of Rare Neurological Diseases
5.1.2 Favourable Pipeline Drugs and Robust Research Activities for the Treatment of Rare Neurological Diseases
5.2 Key Restraints
5.2.1 High Treatment Cost for Rare Neurological Diseases
5.3 Key Market Opportunities
5.3.1 Increasing Awareness of Rare Neurological Diseases Coupled with Developing Healthcare Infrastructure
5.4 Future Trend
5.4.1 Artificial Intelligence for the Treatment of Rare Neurological Diseases
5.5 Impact Analysis
6. Rare Neurological Disease Treatment Market – North America Analysis
6.1 North America Rare Neurological Disease Treatment Market Revenue Forecasts and Analysis
7. North America Rare Neurological Disease Treatment Market Analysis And Forecasts To 2027 – By Indication
7.1 Overview
7.2 North America Rare neurological disease treatment Market, By Indication 2019 & 2027 (%)
7.2.1 North America Rare neurological disease treatment Market Revenue and Forecasts to 2027, By Indication (US$ Mn)
7.3 Narcolepsy
7.3.1 Overview
7.3.2 North America Narcolepsy Market Revenue and Forecast to 2027 (US$ Mn)
7.4 Amyotrophic Lateral Sclerosis
7.4.1 Overview
7.4.2 North America Amyotrophic Lateral Sclerosis Market Revenue and Forecast to 2027 (US$ Mn)
7.5 Alzheimer’s Disease
7.5.1 Overview
7.5.2 North America Alzheimer’s Disease Market Revenue and Forecast to 2027 (US$ Mn)
7.6 Multiple Sclerosis
7.6.1 Overview
7.6.2 North America Multiple Sclerosis Market Revenue and Forecast to 2027 (US$ Mn)
7.7 Spinal Muscular Atrophy (SMA)
7.7.1 Overview
7.7.2 North America Spinal Muscular Atrophy Market Revenue and Forecast to 2027 (US$ Mn)
7.8 Duchenne Muscular Dystrophy
7.8.1 Overview
7.8.2 North America Duchenne Muscular Dystrophy Market Revenue and Forecast to 2027 (US$ Mn)
7.9 Other Indications
7.9.1 Overview
7.9.2 North America Other Indications Market Revenue and Forecast to 2027 (US$ Mn)
8. North America Rare Neurological Disease Treatment Market Analysis– By Drug Type
8.1 Overview
8.2 North America Rare neurological disease treatment Market, By Drug Type 2019-2027 (%)
8.2.1 North America Rare Neurological Disease Treatment Market Revenue and Forecasts to 2027, By Drug Type (US$ Mn)
8.3 Organic Compounds
8.3.1 Overview
8.3.2 North America Organic Compounds Market Revenue and Forecasts to 2027 (US$ Mn)
8.4 Biologics
8.4.1 Overview
8.4.2 North America Biologics Market Revenue and Forecasts to 2027 (US$ Mn)
9. North America Rare Neurological Disease Treatment Market Analysis– By Distribution Channel
9.1 Overview
9.2 North America Rare Neurological Disease Treatment Market, By Distribution Channel 2019 & 2027 (%)
9.2.1 North America Rare Neurological Disease Treatment Market Revenue and Forecasts to 2027, By Distribution Channel (US$ Mn)
9.3 Online Pharmacies
9.3.1 Overview
9.3.2 North America Online Pharmacies Market Revenue and Forecast to 2027 (US$ Mn)
9.4 Hospital Pharmacies
9.4.1 Overview
9.4.2 North America Hospital Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
9.5 Retail Pharmacies
9.5.1 Overview
9.5.2 North America Retail Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
10. North America Rare Neurological Disease Treatment Market Analysis– By Mode of Administration
10.1 Overview
10.2 North America Rare Neurological Disease Treatment Market, By Mode of Administration 2019 & 2027 (%)
10.2.1 North America Rare Neurological Disease Treatment Market Revenue and Forecasts to 2027, By Mode of Administration (US$ Mn)
10.3 Oral
10.3.1 Overview
10.3.2 North America Oral Market Revenue and Forecast to 2027 (US$ Mn)
10.4 Injectable
10.4.1 Overview
10.4.2 North America Injectable Market Revenue and Forecasts to 2027 (US$ Mn)
11. Rare Neurological Disease Treatment Market Revenue and Forecasts To 2027 – Geographical Analysis
11.1 North America Rare Neurological Disease Treatment Market Revenue and Forecasts To 2027
11.1.1 Overview
11.1.2 North America: Rare Neurological Disease Treatment Market, by Key Country – Revenue (2019) (USD Million)
11.1.3 North America: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)
11.1.4 North America: Rare Neurological Disease Treatment Market, by Indication, 2018–2027 (USD Million)
11.1.5 North America: Rare Neurological Disease Treatment Market, by Drug Type, 2018–2027 (USD Million)
11.1.6 North America: Rare Neurological Disease Treatment Market, by Mode of Administration, 2018–2027 (USD Million)
11.1.7 North America: Rare Neurological Disease Treatment Market, by Distribution Channel, 2018–2027 (USD Million)
11.1.8 North America: Rare Neurological Disease Treatment Market, by Country, 2019& 2027 (%)
11.1.9 US: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)
11.1.9.1 US: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)
11.1.9.2 US: Rare Neurological Disease Treatment Market, by Indication, 2018–2027 (USD Million)
11.1.9.3 US: Rare Neurological Disease Treatment Market, by Drug Type, 2018–2027 (USD Million)
11.1.9.4 US: Rare Neurological Disease Treatment Market, by Mode of Administration, 2018–2027 (USD Million)
11.1.9.5 US: Rare Neurological Disease Treatment Market, by Distribution Channel, 2018–2027 (USD Million)
11.1.10 Canada: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)
11.1.10.1 Canada: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)
11.1.10.2 Canada: Rare Neurological Disease Treatment Market, by Indication, 2018–2027 (USD Million)
11.1.10.3 Canada: Rare Neurological Disease Treatment Market, by Drug Type, 2018–2027 (USD Million)
11.1.10.4 Canada: Rare Neurological Disease Treatment Market, by Mode of Administration, 2018–2027 (USD Million)
11.1.10.5 Canada: Rare Neurological Disease Treatment Market, by Distribution Channel, 2018–2027 (USD Million)
11.1.11 Mexico: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)
11.1.11.1 Mexico: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)
11.1.11.2 Mexico: Rare Neurological Disease Treatment Market, by Indication, 2018–2027 (USD Million)
11.1.11.3 Mexico: Rare Neurological Disease Treatment Market, by Drug Type, 2018–2027 (USD Million)
11.1.12 Mexico: Rare Neurological Disease Treatment Market, by Mode of Administration, 2018–2027 (USD Million)
11.1.12.1 Mexico: Rare Neurological Disease Treatment Market, by Distribution Channel, 2018–2027 (USD Million)
12. Impact Of COVID-19 Pandemic On North America Rare Neurological Diseases Treatment Market
12.1 North America: Impact Assessment of COVID-19 Pandemic
13. North America Rare neurological disease treatment Market Industry Landscape
13.1 Overview
13.2 Organic Growth Strategies
13.2.1 Overview
14. Company Profiles
14.1 Johnson & Johnson Services, Inc.
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Merck & Co., Inc.
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Pfizer Inc.
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Novartis AG
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 GlaxoSmithKline plc.
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
15. Appendix
15.1 About The Insight Partners
15.2 Glossary of TermsLIST OF TABLES
Table 1. North America Rare neurological disease treatment Market Revenue and Forecasts To 2027, By Indication (US$ Mn)
Table 2. North America Rare Neurological Disease Treatment Market Revenue and Forecasts To 2027, By Drug Type (US$ Mn)
Table 3. North America Rare Neurological Disease Treatment Market Revenue and Forecasts To 2027, By Distribution Channel (US$ Mn)
Table 4. North America Rare Neurological Disease Treatment Market Revenue and Forecasts To 2027, By Mode of Administration (US$ Mn)
Table 5. North America Rare Neurological Disease Treatment Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 6. North America Rare Neurological Disease Treatment Market, by Drug Type – Revenue and Forecast to 2027 (USD Million)
Table 7. North America Rare Neurological Disease Treatment Market, by Mode of Administration – Revenue and Forecast to 2027 (USD Million)
Table 8. North America Rare Neurological Disease Treatment Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 9. US Rare Neurological Disease Treatment Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 10. US Rare Neurological Disease Treatment Market, by Drug Type – Revenue and Forecast to 2027 (USD Million)
Table 11. US Rare Neurological Disease Treatment Market, by Mode of Administration – Revenue and Forecast to 2027 (USD Million)
Table 12. US Rare Neurological Disease Treatment Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 13. Canada Rare Neurological Disease Treatment Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 14. Canada Rare Neurological Disease Treatment Market, by Drug Type – Revenue and Forecast to 2027 (USD Million)
Table 15. Canada Rare Neurological Disease Treatment Market, by Mode of Administration – Revenue and Forecast to 2027 (USD Million)
Table 16. Canada Rare Neurological Disease Treatment Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 17. Mexico Rare Neurological Disease Treatment Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 18. Mexico Rare Neurological Disease Treatment Market, by Drug Type – Revenue and Forecast to 2027 (USD Million)
Table 19. Mexico Rare Neurological Disease Treatment Market, by Mode of Administration – Revenue and Forecast to 2027 (USD Million)
Table 20. Mexico Rare Neurological Disease Treatment Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 21. Recent Inorganic Growth Strategies In The Rare Neurological Disease Treatment Market
Table 22. Recent Organic Growth Strategies In The Rare Neurological Disease Treatment Market
Table 23. Glossary of Terms, Rare Neurological Disease Treatment Market
LIST OF FIGURES
Figure 1. Rare Neurological Disease Treatment Market Segmentation
Figure 2. North America Rare Neurological Disease Treatment Market Overview
Figure 3. Alzheimer’s Disease Segment Held Largest Share Of Indication Segment In Rare Neurological Disease Treatment Market
Figure 4. US Is Expected To Show Remarkable Growth During The Forecast Period
Figure 5. North America Rare Neurological Disease Treatment Market- Leading Country Markets (US$ Mn)
Figure 6. Rare Neurological Disease Treatment Market, Industry Landscape
Figure 7. Rare Neurological Disease Treatment Market - North America PEST Analysis
Figure 8. Rare Neurological Disease Treatment Market Impact Analysis of Drivers and Restraints
Figure 9. North America Rare Neurological Disease Treatment Market – Revenue Forecasts and Analysis – 2019- 2027
Figure 10. North America Rare neurological disease treatment Market, By Indication 2019 & 2027 (%)
Figure 11. North America Narcolepsy Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 12. North America Amyotrophic Lateral Sclerosis Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 13. North America Alzheimer’s Disease Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 14. North America Multiple Sclerosis Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 15. North America Spinal Muscular Atrophy Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 16. North America Duchenne Muscular Dystrophy Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 17. North America Other Indications Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 18. North America Rare neurological disease treatment Market, by Drug Type 2019 & 2027 (%)
Figure 19. North America Organic Compounds Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 20. North America Biologics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 21. North America Rare Neurological Disease Treatment Market, By Distribution Channel 2019 & 2027 (%)
Figure 22. North America Online Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 23. North America Hospital Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 24. North America Retail Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 25. North America Rare Neurological Disease Treatment Market, By Mode of Administration 2019 & 2027 (%)
Figure 26. North America Oral Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 27. North America Injectable Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 28. North America: Rare Neurological Disease Treatment Market, by Key Country – Revenue (2019) (USD Million)
Figure 29. North America Rare Neurological Disease Treatment Market Revenue and Forecast to 2027 (USD Million)
Figure 30. North America: Rare Neurological Disease Treatment Market, by Country, 2019 & 2027 (%)
Figure 31. US: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)
Figure 32. Canada: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)
Figure 33. Mexico: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)
Figure 34. Impact of COVID-19 Pandemic In North American Country Markets
The List of Companies - North America Rare Neurological Disease Treatment Market
- Allergan plc.
- Bayer AG
- GlaxoSmithKline plc.
- Johnson & Johnson Services Inc.
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi
- Teva Pharmaceutical Industries Ltd
- Takeda Pharmaceutical Company Limited
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America rare neurological disease treatment market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the North America rare neurological disease treatment market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth regional market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.